With Axial associates now based in the UK, EU and US, our reach into investment and capital markets is extensive. Following the addition of two advisors this year we look forward to 2022 being a stellar year for providing investment.
We want to say well done to our team member Chris in the US for securing the mandate for AVM’s current investment round, to accelerate the development of their immuno-therapy technology. This immuno-response basis to their treatment may also result in a reduction in the number of chemotherapy cycles needed for a complete response, bringing about greater efficacy with reduced side effects.
Whilst medical isn’t Chris’s only focus area, it’s great to see our advisory services bringing value to such a worthwhile technology.